SDGR Schrodinger, Inc.

Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. Schrödinger was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in August 1990 and is headquartered in New York, NY.

$39.25  +3.07 (8.49%)
As of 12/07/2021 11:54:26 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Health Information Services
Index country:  USA
Country of incorporation:  USA
IPO date:  02/06/2020
Outstanding shares:  61,731,520
Average volume:  1,071,965
Market cap:   $2,242,706,122
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    80810D103
ISIN:        US80810D1037
Sedol:      BKV28S8
Valuation   (See tab for details)
PE ratio:   -27.64
PB ratio:   4.42
PS ratio:   17.97
Return on equity:   -13.94%
Net income %:   -64.76%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy